Skip to content

002644.SZ

Lanzhou Foci Pharmaceutical Co., Ltd.

SZSE · Healthcare · C 制造业 · CN

CNY 8.18
−0.24%
Ask drillr

Year over year

Reported trailing growth

Revenue
-1.2%
EBITDA
EBIT
-0.2%
EPS
-14.0%
Free cash flow
+397.2%
Operating cash flow
+267.0%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-4.2%
EBITDA
-14.2%
EBIT
-22.8%
Net income
-23.2%
EPS
-23.2%
Free cash flow
+54.2%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026